374 related articles for article (PubMed ID: 16012725)
1. The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo.
Nishi M; Abe Y; Fujimori S; Hamamoto A; Inoue Y; Miyazaki N; Oida Y; Ikoma N; Ohnishi Y; Yamazaki H; Ueyama Y; Nakamura M
Oncol Rep; 2005 Aug; 14(2):421-4. PubMed ID: 16012725
[TBL] [Abstract][Full Text] [Related]
2. The subunits of glutamate cysteine ligase enhance cisplatin resistance in human non-small cell lung cancer xenografts in vivo.
Fujimori S; Abe Y; Nishi M; Hamamoto A; Inoue Y; Ohnishi Y; Nishime C; Matsumoto H; Yamazaki H; Kijima H; Ueyama Y; Inoue H; Nakamura M
Int J Oncol; 2004 Aug; 25(2):413-8. PubMed ID: 15254739
[TBL] [Abstract][Full Text] [Related]
3. The modifier subunit of glutamate cysteine ligase (GCLM) is a molecular target for amelioration of cisplatin resistance in lung cancer.
Inoue Y; Tomisawa M; Yamazaki H; Abe Y; Suemizu H; Tsukamoto H; Tomii Y; Kawamura M; Kijima H; Hatanaka H; Ueyama Y; Nakamura M; Kobayashi K
Int J Oncol; 2003 Nov; 23(5):1333-9. PubMed ID: 14532974
[TBL] [Abstract][Full Text] [Related]
4. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.
Némati F; Daniel C; Arvelo F; Legrier ME; Froget B; Livartowski A; Assayag F; Bourgeois Y; Poupon MF; Decaudin D
Anticancer Drugs; 2010 Jan; 21(1):25-32. PubMed ID: 19823076
[TBL] [Abstract][Full Text] [Related]
6. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) correlates with cisplatin resistance in human non-small cell lung cancer xenografts.
Nakagawa T; Inoue Y; Kodama H; Yamazaki H; Kawai K; Suemizu H; Masuda R; Iwazaki M; Yamada S; Ueyama Y; Inoue H; Nakamura M
Oncol Rep; 2008 Aug; 20(2):265-70. PubMed ID: 18636185
[TBL] [Abstract][Full Text] [Related]
7. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
8. Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?
Merk J; Rolff J; Dorn C; Leschber G; Fichtner I
Eur J Cardiothorac Surg; 2011 Jul; 40(1):e29-33. PubMed ID: 21420313
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
10. Gonadotropin regulation of glutamate cysteine ligase catalytic and modifier subunit expression in rat ovary is subunit and follicle stage specific.
Tsai-Turton M; Luderer U
Am J Physiol Endocrinol Metab; 2005 Sep; 289(3):E391-402. PubMed ID: 15811874
[TBL] [Abstract][Full Text] [Related]
11. Genomic-wide cDNA microarray screening to correlate gene expression profile with chemoresistance in patients with advanced lung cancer.
Oshita F; Ikehara M; Sekiyama A; Hamanaka N; Saito H; Yamada K; Noda K; Kameda Y; Miyagi Y
J Exp Ther Oncol; 2004 Jul; 4(2):155-60. PubMed ID: 15500010
[TBL] [Abstract][Full Text] [Related]
12. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway.
Liu LZ; Zhou XD; Qian G; Shi X; Fang J; Jiang BH
Cancer Res; 2007 Jul; 67(13):6325-32. PubMed ID: 17616691
[TBL] [Abstract][Full Text] [Related]
13. Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features.
Westerman BA; Neijenhuis S; Poutsma A; Steenbergen RD; Breuer RH; Egging M; van Wijk IJ; Oudejans CB
Clin Cancer Res; 2002 Apr; 8(4):1082-6. PubMed ID: 11948117
[TBL] [Abstract][Full Text] [Related]
14. Preclinical assessment of cisplatin-based therapy versus docetaxel-based therapy on a panel of human non-small-cell lung cancer xenografts.
Némati F; Bras-Gonçalves R; Fontaine JJ; de Pinieux G; De Cremoux P; Chapelier A; Daniel C; Laurent-Puig P; Livartowski A; Judde JG; Bordier V; Poupon MF; Decaudin D
Anticancer Drugs; 2009 Nov; 20(10):932-40. PubMed ID: 19741504
[TBL] [Abstract][Full Text] [Related]
15. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy.
Zeng-Rong N; Paterson J; Alpert L; Tsao MS; Viallet J; Alaoui-Jamali MA
Cancer Res; 1995 Nov; 55(21):4760-4. PubMed ID: 7585500
[TBL] [Abstract][Full Text] [Related]
16. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
[TBL] [Abstract][Full Text] [Related]
17. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts.
Zhang W; Chen Y; Wei H; Zheng C; Sun R; Zhang J; Tian Z
Clin Cancer Res; 2008 Oct; 14(20):6432-9. PubMed ID: 18927282
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of constitutive signal transducer and activator of transcription 3 mRNA in cisplatin-resistant human non-small cell lung cancer cells.
Ikuta K; Takemura K; Kihara M; Nishimura M; Ueda N; Naito S; Lee E; Shimizu E; Yamauchi A
Oncol Rep; 2005 Feb; 13(2):217-22. PubMed ID: 15643501
[TBL] [Abstract][Full Text] [Related]
19. The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine.
Guan J; Lo M; Dockery P; Mahon S; Karp CM; Buckley AR; Lam S; Gout PW; Wang YZ
Cancer Chemother Pharmacol; 2009 Aug; 64(3):463-72. PubMed ID: 19104813
[TBL] [Abstract][Full Text] [Related]
20. betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer.
McCarroll JA; Gan PP; Liu M; Kavallaris M
Cancer Res; 2010 Jun; 70(12):4995-5003. PubMed ID: 20501838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
